FORME (REV 11	PTO-139 1-98)	00(Modified) U.S. DEPARTMENT	OF COMMERCEPATENTAND TRADEMARKOFFICE	ATTORNEYSDOCKETNUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES PU3514USW					
		DESIGNATED/ELECTE	U.S. APPLICATIONNO. (IF KNOWN, SEE 37 CFR		
CONCERNING A FILING UNDER 35 U.S.C. 371 09/787327					
INTE		TIONAIAPPLICATIONNO. PCT/EP99/06886	INTERNATIONAIFILINGDATE 17 September 1999	PRIORITYDATECLAIMED 18 September 1998	
	EOFI	NVENTION			
ANT	1VIR	AL COMBINATIONS			
A DDT	A DRI TO A NEW YORD DO TO IT IS				
	APPLICANT(SFOR DO/EO/US BROWN, Nathaniel A.; CONDREAY, Lynn, D.; GRAY, Douglas, Fraser; RUBIN, Marc				
L					
Appli	cant l	nerewith submits to the United Sta	tes Designated/Elected Office (DO/EO/US) th	ne following items and other information:	
1.	\boxtimes	This is a FIRST submission of i	tems concerning a filing under 35 U.S C. 371.		
2.		This is a SECOND or SUBSEQ	UENT submission of items concerning a filing	g under 35 U S C. 371.	
3.	X		in national examination procedures (35 U.S.C of the applicable time limit set in 35 U.S.C. 3		
4.	×			19th month fron the earliest claimed priority date.	
5.	X		ication as filed (35 U S.C 371 (c) (2))		
			(required only if not transmitted by the Inter-	national Bureau).	
			the International Bureau. pplication was filed in the United States Rece	aying Office (RO/US)	
6.		-		-	
7.	X				
8.	X				
	a. are transmitted herewith (required only if not transmitted by the International Bureau)				
	b 🛛 have been transmitted by the International Bureau.				
	c. \square have not been made; however, the time limit for making such amendments has NOT expired.				
9.		d. have not been made an	d will not be made. to the claims under PCT Article 19 (35 U.S.C	2. 371(a)(3))	
9. 10.	\boxtimes		rentor(s) (35 U.S.C. 371 (c)(4)). Condrea		
11.	×				
12.		- Tresport (Contraction Temperature Temper			
	(35 U.S.C. 371 (c)(5)).				
Items 13 to 20 below concern document(s) or information included:					
13.	×		ement under 37 CFR 1 97 and 1.98.	il at CEN ago, tager	
14. 15.		An assignment document for rec A FIRST preliminary amendment	ording A separate cover sheet in compliance	with 37 CFR 3 28 and 3.31 is included	
16.		A SECOND or SUBSEQUENT			
17.		A substitute specification.	E		
18.		A change of power of attorney a	nd/or address letter		
19.	\boxtimes	Certificate of Mailing by Express Mail			
20.	\boxtimes	Other items or information:			
		Copy of Form PCT/RO/101			
	Copy of PCT Publication Cover Sheet				
1					
1		1			

Page 1 of 2

PCTUS1/REV03

532 Rec'd PC ... 16 MAR 2001

U.S. APPLICATION	PPLICATIONNO. (IF KNOWN, SEE 37 CFR INTERNATIONALAPPLICATIONNO.		ATTORNEY	SDOCKETNUMBER			
n c	09/787327 PCT/EP99/06886				PU3	514USW	
21. The fo	1. The following fees are submitted				CALCULATIONS	S PTOUSEONLY	
	L FEE (37 CFR 1.492 (a) (1) -					O. ECCEPTION.	J TTO OSE ONE T
□ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO					.000.00		
USPTO but	preliminary examination fee (37 Internation Search Report prepare	ed by the EPO or JPO		. 9	8860.00		
International	l preliminary examination fee (37 onal search fee (37 CFR 1 445(a))	CFR 1.482) not paid	to USPTC)	7510.00	!	
☐ International	l preliminary examination fee pairs did not satisfy provisions of PC	d to USPTO (37 CFR	1 482)		6710.00 6690.00		
☐ International	l preliminary examination fee pairs satisfied provisions of PCT Art	d to USPTO (37 CER	1.482)		3100.00		
	ENTER APPROPRIA	ATE BASIC FE	EE AM	OUNT	=	\$860.00	
months from the ea	90 for furnishing the oath or declar rliest claimed priority date (37 Cl	ration later than FR 1.492 (e)).	□ 20	0 🗆	30	\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXT	`RA	RA	TE		
Total claims	15 - 20 =	0		x \$1	3.00	\$0.00	
Independent claims		1			0.00	\$80.00	
Multiple Dependen	t Claims (check if applicable).	ABOVE CALO	NETE A DE	LONG		\$0.00	
Reduction of 1/2 fo	r filing by small entity, if applica				=	\$940.00	
must also be filed ((Note 37 CFR 1.9, 1 27, 1.28) (che	eck if applicable).				\$0.00	
	Mar		SUB'	ΓΟΤΑΙ		\$940.00	
Processing fee of \$1 months from the ear	130.00 for furnishing the English rliest claimed priority date (37 CI	translation later than FR 1.492 (f))	□ 20) [30 +	60.00	
		TOTAL NAT	TONAI	FFF	=	\$0.00 \$940.00	
Fee for recording th	ne enclosed assignment (37 CFR 1					3940.00	
accompanied by an	appropriate cover sheet (37 CFR	3.28, 3.31) (check if	applicable	e)		\$0.00	
	TOTAL FEES ENCLOSED =		\$940.00 Amount to be:				
						refunded	\$
						charged	\$
A check in the amount of to cover the above fees is enclosed. Please charge my Deposit Account No 07-1392 in the amount of \$940.00 to cover the above fees A duplicate copy of this sheet is enclosed							
The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No 07-1392 A duplicate copy of this sheet is enclosed.							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition of revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.							
SEND ALL CORRESPONDENCE TO:							
David J. Levy Glavo Wellcome Inc. SIGNATURE							
Glaxo Wellcome Inc. Global Intllectual Property Dept.			/	/	1010		
Five Moore Drive, PO Box 13398			Karen L. Prus				
Research Triangle Park, NC 27709			NAME				
Telephone: 919-483-2370 Fax: 919-483-7988			39,337				
				REGIS	[RATIO]	NUMBER	
				March	14 2	001	
				DATE	-/-		

Page 2 of 2

532 Rec'd PCT/PTO 16 MAR 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Nathaniel A. BROWN et al

International Application No.:

PCT/EP99/06886

International Filing Date:

17 September 1999

Title:

ANTIVIRAL COMBINATIONS

Commissioner of Patents Washington, D.C. 20231

FIRST PRELIMINARY AMENDMENT

Dear Sir:

The above identified application is being transmitted herewith for entry in the US National Phase under Chapter II of the PCT for the purpose of adding the priority information. Please amend the application as follows:

In the Abstract:

Please substitute the attached Abstract, which has been placed on a separate sheet of paper according to US practice, as required under 37 CFR 1.72(b)

In the Specification:

On the first line of the specification, after the Title, please add:

--This application is filed pursuant to 35 U.S.C. §371 as a United States National Phase Application of International Application No. PCT/EP99/06886 filed 17 September 1999, which claims priority from GB9820420.9 filed 18 September 1998.--

In the Claims:

Please delete Claim 11 and Claims 16-21.

Please amend the Claims as follows:

Clean Copy of Amended Claims

Claim 1 (Amended in IPER) A combination comprising (2R,cis)-4-amino-1-(2hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and а second therapeutic agent, bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine а pharmaceutically acceptable derivative thereof wherein (2R,cis)-4-amino-1-(2hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight.

Claim 2. A combination according to claim 1 wherein the ratio is in the range 25:1 to 15:1 by weight of active ingredients.

Claim 3 (Amended here and in IPER) A combination according to claim 1 for use in medicine.

Claim 4 (Amended here and in IPER) A pharmaceutical formulation comprising a combination according to claim 1 in association with one or more pharmaceutically acceptable carriers therefor.

Claim 5 (Amended in IPER) A pharmaceutical formulation for use in the treatment of HBV comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or а pharmaceutically acceptable derivative thereof. and bis(pivaloyloxymethyl)(9-[R)-2-(phosphonomethoxy)ethyl]adenine or а pharmaceutically acceptable derivative thereof wherein (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight.

Claim 6 (Amended here and IPER) A formulation according to claim 4 in unit dosage form.

Claim 7 (Amended here and IPER) A formulation according to claim 4 suitable for oral administration.

Claim 8 (Amended) A formulation according to claim 5 comprising between 25 to 150 mg of lamivudine and 5 to 60 mg adefovir dipivoxil.

Claim 9 A formulation according to claim 8 comprising 100 mg of lamivudine and 10 mg adefovir dipivoxil.

Claim 10 A method for the treatment of a mammal, including a human, with an HBV infection comprising administration of a therapeutically effective amount of a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or а pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethylladenine or a pharmaceutically acceptable derivative thereof. and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or pharmaceutically а acceptable derivative thereof.

Delete Claim 11

Claim 12 (Amended) A method according to claim 10 wherein the combination is administered simultaneously.

Claim 13 (Amended) A method according to claim 10 wherein the combination is administered sequentially.

Claim 14 (Amended) A method according to claim 10 wherein the combination is administered as a single combined formulation.

Claim 15 (Amended) A method as claimed in claim 10 for the treatment of an HBV infection resistant to nucleoside and/or non-nucleoside inhibitors of the replication of the hepatitis B virus.

Delete Claims 16-21

Claim 22 (Amended in IPER) A patient pack comprising of at least one active ingredient selected from (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one, and bis(pivaloyloxymethyl)(9-[2-

(phosphonomethoxy)ethyl]adenine and an information insert containing directions on the use of both active ingredients together in combination.

REMARKS

Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information. The claims have been amended to place them in form appropriate to US practice and to reduce the filing fee by removing multiple dependency. Claims 1, 3, 4, and 5 have been amended to parallel the amended claims as indicated in the PCT International Preliminary Examination Report. Claims 11 and 16-21 have been deleted. It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted;

Date: March 14, 2001

Karen L. PRUS

Attorney of Record, Reg. No 39,337

Glaxo Wellcome Inc. Global Intellectual Property Department Five Moore Drive, PO Box 13398

Research Triangle Park, NC 27709-3398

Telephone: 919-483-3323

Fax: 919-483-7988

ANTIVIRAL COMBINATIONS

Abstract

The present invention relates to therapeutic combinations comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one (lamivudine) and а second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine. (PMEA or adefovir) and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine, (the oral prodrug of PMEA, adefovir dipivoxil) which have anti-hepatitis B virus (HBV) activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HBV infections including infections with HBV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.

Version With Markings to Show Changes Made to Claims

Claim 1 (Amended in IPER) A combination comprising (2R,cis)-4-amino-1-(2hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent [selected from (9-I(R)-2-(phosphonomethoxy)ethyl]adenine or а pharmaceutically acceptable derivative thereof. bis(pivaloyloxymethyl)(9-[(R)-2and] (phosphonomethoxy)ethyl]adenine pharmaceutically or а acceptable derivative thereof (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3wherein oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight.

Claim 2 A combination according to claim 1 wherein the ratio is in the range 25:1 to 15:1 by weight of active ingredients.

Claim 3 (Amended here and in IPER) A combination according to [any one of] claim[s] 1 [or 3] for use in medicine.

Claim 4 (Amended here and in IPER) A pharmaceutical formulation comprising a combination according to [any one of] claim[s] 1 [to 3] in association with one or more pharmaceutically acceptable carriers therefor.

Claim 5 (Amended in IPER) A pharmaceutical formulation for use in the treatment of HBV comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or pharmaceutically а acceptable derivative thereof. bis(pivaloyloxymethyl)(9-[R)-2and (phosphonomethoxy)ethyl]adenine or а pharmaceutically acceptable derivative thereof wherein (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight.

Claim 6. (Amended here and in IPER) A formulation according to claim[s] 4 [or 5] in unit dosage form.

Claim 7. (Amended here and in IPER) A formulation according to [any one of] claim[s] 5 [to 6] suitable for oral administration.

Claim 8. (Amended) A formulation according to [any one of] claim[s] 5 [to 7] comprising between 25 to 150 mg of lamivudine and 5 to 60 mg adefovir dipivoxil.

Claim 9. A formulation according to claim 8 comprising 100 mg of lamivudine and 10 mg adefovir dipivoxil.

Claim 10. A method for the treatment of a mammal, including a human. with an HBV infection comprising administration of a therapeutically effective amount of a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethylladenine or a pharmaceutically acceptable derivative thereof. and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or pharmaceutically acceptable а derivative thereof.

Claim 11 (Deleted)

Claim 12. (Amended) A method according to claim 10 [or claim 11] wherein the combination is administered simultaneously.

Claim 13. (Amended) A method according to claim 10 [or claim 11] wherein the combination is administered sequentially.

Claim 14. (Amended) A method according to claim 10 [or claim 11] wherein the combination is administered as a single combined formulation.

Claim 15. (Amended) A method as claimed in [any one of] claim[s] 10 [to 14] for the treatment of an HBV infection resistant to nucleoside and/or non-nucleoside inhibitors of the replication of the hepatitis B virus

Claim 16 (Deleted)

Claim 17 (Deleted)

Claim 18 (Deleted)

Claim 19 (Deleted)

Claim 20 (Deleted)

Claim 21 (Deleted)

Claim 22. (Amended in IPER) A patient pack comprising of at least one active ingredient selected from (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one, and bis(pivaloyloxymethyl)(9-[2-(phosphonomethoxy)ethyl]adenine and an information insert containing directions on the use of both active ingredients together in combination.

10

10 MAR 20 PCT/EP99/06886

09/787327

1

Antiviral Combinations

The present invention relates to therapeutic combinations comprising (2R,cis)-4amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one (lamivudine) and second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine, (PMEA or adefovir) and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine, [the oral prodrug of PMEA, adefovir dipivoxil]. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HBV infections including infections with HBV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors of the replication of the hepatitis B virus.

Hepatitis B is a viral disease transmitted orally or parentally by contaminated material such as blood or blood products, contaminated needles, sexually, and vertically from infected or carrier mothers to their off-spring. In those areas of the world where the disease is common, vertical transmission at an early age results in a high proportion of infected individuals becoming chronic carriers of hepatitis B. An estimated 350 million people world-wide are chronically infected with hepatitis B and as many as 150 million may die from liver disease in the absence of intervention.

Currently, the only established approach to treatment of hepatitis B is repeated injections of interferon, which may be associated with unpleasant side effects, and produces a long lasting response in only one third or less of those treated. Interferon is an immune modulator designed to boost the disease fighting ability of the immune system.

Lamivudine has been reported to be effective against HBV in a two year study, showing that most patients showed substantially reduced levels of viral replication with 52% maintaining undetectable levels of virus thorough to the end of the second year.

Adefovir has been reported to posses anti-HBV activity in vitro, and the oral prodrug of adefovir, adefovir dipivoxil, has been shown to be active against HBV replication in vivo and is currently in phase II clinical studies with patients who have chronic hepatitis B viral infection.

5

There has been a report that there is lack of cross-resistance to PMEA for Human hepatitis B DNA polymerase which expresses lamivudine codons, *X. Xiong et al.*(Hepatology Vol 26, No. 4, Pt. 2, 1997, Abstract No. 1211).

10

The use of combinations of the invention may give rise to equivalent antiviral effect with reduced toxicity, or an increase in drug efficacy because synergy between compounds occurs. Lower overall drug doses will also possibly reduce the frequency of occurrence of drug resistant variants of HBV.

We have now found that lamivudine exhibits unexpected advantages when used in combination with adefovir. In particular the combinations shows a statistically significant synergistic anti-HBV effect. Early results have shown that the combination of lamivudine and adefovir dipivoxil also exhibits a synergistic anti-HBV-effect. It is a feature of this invention that the use of these drug combinations will provide synergistic antiviral effects, more complete viral suppression, viral suppression over longer periods, limit the emergence of drug resistant HBV mutants and allow better management of drug related toxicites. The use of these drug combinations may also result in a decrease of the number of, for example, tablets administered a day, therefore may increase patient compliance.

25

As will be appreciated by those skilled in the art, references herein to treatment extend to prophylaxis as well as to the treatment of established infections and symptoms.

30

35

Pharmaceutically acceptable salts of lamivudine, adefovir, or adefovir dipivoxil include those derived from pharmaceutically acceptable inorganic and organic acids. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene- p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic,

malonic, naphthalene-2-sulphonic and benzenesulphonic acids. Other acids such as oxalic acid, while not in themselves pharmaceutically acceptable may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium), ammonium and NR_{4+} (where R is C_{1-4} alkyl) salts.

Preferred esters of lamivudine, adefovir or adefovir dipivoxil are independently selected from the following group: (1) carboxylic acid esters in which the noncarbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, methyl, n-propyl, t-butyl, or nbutyl), cycloalkyl, alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted by, for example, halogen, C_{1-4} alkyl, or C_{1-4} alkoxy), or amino; (2) sulphonate esters, such as alkyl- or aralkylsulphonyl (for example, methanesulphonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); and (4) phosphonate esters. In such esters, unless otherwise specified, any alkyl moiety present advantageously contains from 1 to 18 carbon atoms, particularly from 1 to 6 carbon atoms, more particularly from 1 to 4 carbon atoms. Any cycloalkyl moiety present in such esters advantageously contains from 3 to 6 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group. Any reference to any of the above compounds also includes a reference to a physiologically acceptable salt thereof.

Particularly preferred esters are the mono-, di-, and triphosphate esters of lamivudine (which may be optionally blocked), or any other compound which upon administration to a human subject is capable of providing (directly or indirectly) said mono-, di-, or triphosphate ester.

Thus according to one aspect, the present invention provides a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second

5

10

30

25

therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof.

5

Preferably the second therapeutic agent is bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof.

10

Combinations as described above may herein after be referred to as combinations according to the invention.

As used herein "pharmaceutically acceptable derivative" includes any pharmaceutically acceptable salt, ester or salt of such ester, of lamivudine, adefovir or adefovir dipivoxil or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) such a compound or an antivirally active metabolite or residue thereof.

The present invention further provides combinations according to the invention for use in therapy, particularly in the treatment of an HBV infection including infections resistant to nucleoside and/or non-nucleoside inhibitors of the replication of the hepatitis B virus.

25

According to another aspect, the present invention provides a method for the treatment of a mammal, including a human, suffering from an HBV infection comprising administration of a therapeutically effective amount of a combination according to the invention.

30

It will be appreciated that the compounds of the combination may be administered simultaneously, either in the same or different pharmaceutical composition, or sequentially. If there is sequential administration, the delay in administering the second active ingredient should not be such as to lose the benefit of a synergistic therapeutic effect of the combination of the active ingredients. It will also be understood that lamivudine, and adefovir dipivoxil, or the pharmaceutically acceptable derivatives thereof or adefovir or the

pharmaceutically acceptable derivatives thereof, whether presented simultaneously or sequentially, may be administered individually or in any combination thereof. Lamivudine, and adefovir dipivoxil or adefovir are preferably administered simultaneously or sequentially in separate pharmaceutical formulations, most preferably simultaneously.

Preferably the combination according to the invention is administered as a single combined formulation.

The present invention also provides the use of lamivudine in the manufacture of a medicament for administration simultaneously or sequentially with adefovir or adefovir dipivoxil for the treatment of HBV infections. It will be appreciated that lamivudine, adefovir dipivoxil, or adefovir or any combination thereof (excluding adefovir and adefovir dipivoxil), may be used in the manufacture of the above medicament.

A further aspect of the invention is a combination according to the invention wherein the lamivudine and adefovir dipivoxil or adefovir are present in a synergistic ratio.

The synergistic effects of the combination of lamivudine and adefovir dipivoxil or adefovir or pharmaceutically acceptable derivatives thereof are seen over a ratio, for example, of 40:1 to 1:1 (by weight), preferably 25:1 to 15: 1 (by weight).

Conveniently each compound will be employed in the combination in an amount at which it exhibits anti-HBV activity when used alone.

The amount of a combination of lamivudine, adefovir or adefovir dipivoxil required to be effective as an anti-HBV agent will, of course, vary and is ultimately at the discretion of the medical practitioner. The factors to be considered include the route of administration and nature of the formulation, the animal's body weight, age and general condition and the nature and severity of the disease to be treated.

25

30

5

In general for lamivudine a suitable daily dose will be in the range of from about 0.1 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 0.5 to 20 mg per kilogram body weight per day, most preferably in the range of 0.5 to 2 mg per kilogram body weight per day.

5

10

The compound is conveniently administered at a level of about 100 mg per day.

For adefovir dipivoxil a suitable daily dose will be in the range of from about 0.01 to about 10 mg per kilogram body weight of the recipient per day, preferably in the range of 0.01 to 1 mg per kilogram body weight per day, most preferably in the range of 0.01 to 0.05 mg per kilogram body weight per day.

Conveniently adefovir dipivoxil is administered at a level of about 10 mg per day.

For adefovir, a suitable daily dose will be in the range of from about 0.01 to about 10 mg per kilogram body weight of the recipient per day, preferably in the range of 0.01 to 1 mg per kilogram body weight per day, most preferably in the range of 0.01 to 0.05 mg per kilogram body weight per day.

Conveniently adefovir is administered at a level of about 10 mg per day.

25

30

Unless otherwise indicated all weights of active ingredients are calculated in terms of the drug <u>per se</u>. In the case of a pharmaceutically acceptable derivatives of lamivudine, adefovir dipivoxil or adefovir, or a solvate of any thereof the figures would be increased proportionately. The desired dose is preferably presented as two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing from 1 to 1500 mg, preferably from 5 to 1000 mg, most preferably from 5 to 500 mg of active ingredient per unit dosage form. Alternatively, if the condition of the recipient so requires, the dose may be administered as a continuous infusion.

The components of the combination which may be referred to as active ingredients may be administered for therapy to an animal e.g. a mammal including a human in a conventional manner.

While it is possible for the active ingredients of the combination to be administered as the raw chemical it is preferable to present them as a pharmaceutical composition. Pharmaceutical compositions according to the present invention comprise a combination according to the invention in association with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents. The carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the formula and not deleterious to the recipient thereof. When the individual components of the combination are administered separately they are generally each presented as a pharmaceutical composition. The references hereinafter to compositions refer unless otherwise stated to compositions containing either the combination or a component thereof.

A combination of lamivudine and adefovir dipivoxil or adefovir or pharmaceutically acceptable derivatives thereof may conveniently be presented as a pharmaceutical composition with one or more pharmaceutically acceptable carrier thereof in a unitary dosage form. A convenient unitary dosage formulation contains the active ingredients in amounts of from 1 mg to 2 g each, for example, 2 mg to 200 mg such as 25 to 150 mg of lamivudine and 5 to 60 mg of adefovir or adefovir dipivoxil.

25

30

5

10

Pharmaceutical compositions may also be prescribed to the patient in "patient packs" containing the whole course of treatment in a single package, usually a blister pack. Patient packs have an advantage over traditional prescriptions, where a pharmacists divides a patients supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in traditional prescriptions. The inclusion of a package insert has been shown to improve patient compliance with the physicians instructions.

It will be understood that the administration of the combination of the invention by means of a single patient pack, or patients packs of each composition, within a package insert diverting the patient to the correct use of the invention is a desirable additional feature of this invention.

5

According to a further aspect of the invention there is provided a patient pack comprising at least one active ingredient of the combination according to the invention and an information insert containing directions on the use of the combination of the invention.

10

According to another aspect the invention provides a double pack comprising in association for separate administration lamivudine and adefovir dipivoxil or adefovir or pharmaceutically acceptable derivatives thereof.

Compositions include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods represent a further feature of the present invention and include the step of bringing into association the active ingredients with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.

25

Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, caplets, cachets or tablets each containing a predetermined amount of the active ingredients; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

30

A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in

25

30

35

5

a suitable machine the active ingredients in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Moulded tablets may be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredients therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.

Preferably the combinations according to the invention are administered orally.

Compositions suitable for topical administration in the mouth include lozenges comprising the active ingredients in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. Compositions for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

Topical administration may also be by means of a transdermal iontophoretic device.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Pharmaceutical formulations suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by admixture of the active

10

25

30

combination with the softened or melted carrier(s) followed by chilling and shaping in moulds.

Formulations suitable for parenteral administration include aqueous and nonaqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents; and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Preferred unit dosage formulations are those containing a daily dose or daily subdose of the active ingredients, as herein before recited, or an appropriate fraction thereof.

It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavouring agents.

The compounds of the combination of the present invention may be obtained in a conventional manner.

Methods for the preparation of lamivudine are described in International Patent Applications Numbers. WO91/17159, and WO 95/29174 incorporated herein by reference.

10

15

20

Methods for the preparation of adefovir are described in European Patent No. 206459, incorporated herein by reference.

Methods for the preparation of adefovir dipivoxil are described in European Patent No. 481214 incorporated herein by reference.

The following examples are intended for illustration only and are not intended to limit the scope of the invention in any way. "Active ingredient" denotes lamivudine, adefovir dipivoxil or adefovir or multiples thereof or a physiologically functional derivative of any of the aforementioned compounds.

Example 1: Tablet Formulation

The following formulations A, B and C are prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.

Formulation A

	mg/tablet
Active Ingredient A	100
Active Ingredient B	30
Lactose B.P.	105
Povidone B.P.	7
Sodium Starch Glycollate	10
Magnesium Stearate	3
	255

Formulation B

	mg/tablet
Active Ingredient A	100

Active Ingredient B	30
Lactose B.P.	75
Avicel PH 101	30
Povidone B.P.	7
Sodium Starch Glycollate	10
Magnesium Stearate	3
	255

Formulation C

	mg/tablet
Active Ingredient A	100
Active Ingredient B	5
Lactose B.P.	100
Starch	25
Povidone	2
Magnesium Stearate	2
	234

The following formulations, D and E, are prepared by direct compression of the admixed ingredients. The lactose in formulation E is of the direct compression type (Dairy Crest - "Zeparox").

Formulation D

	mg/tablet
Active Ingredient A	100
Active Ingredient B	30
Pregelatinized Starch NF15	75
	205

Formulation E

	mg/tablet
Active Ingredient A	100
Active Ingredient B	5
Lactose B.P.	70
Avicel	50
	225

Formulation F (Controlled Release Formulation)

The formulation is prepared by wet granulation of the ingredients with a solution of povidone followed by the addition of magnesium stearate and compression.

	mg/tablet
Active Ingredient A	100
Active Ingredient B	30
Hydroxypropylmethylcellulose	28
(Methocel K4M Premium)	
Lactose B.P.	13
Povidone B.P.	7
Magnesium Stearate	2
	180

Drug release takes place over a period of about 6-8 hours and is complete after 12 hours.

10 Example 2: Capsule Formulations

Formulation A

A capsule formulation is prepared by admixing the ingredients of formulation D in Example 1 above and filling into a two-part hard gelatin capsule. Formulation B (infra) is prepared in a similar manner.

Formulation B

	mg/capsule
Active Ingredient A	100
Active Ingredient B	5
Lactose B.P.	70
Sodium Starch Glycollate	10
Magnesium Stearate	1
	186

Formulation C

	ing/capsule
Active Ingredient A	100
Active Ingredient B	30
Macrogel 4000 B.P.	170
	300

Capsules of formulation C are prepared by melting the Macrogel 4000 B.P., dispersing the active ingredient in the melt and filling the melt into a two-part hard gelatin capsule.

Formulation D

	mg/capsule
Active Ingredient A	100
Active Ingredient B	5
Lecithin	50
Arachis Oil	50
	
	205

20

10

Capsules of formulation D are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules.

5 Formulation E (Controlled Release Capsule)

The following controlled release capsule formulation is prepared by extruding ingredients a, b, and c using an extruder, followed by spheronization of the extrudate and drying. The dried pellets are then coated with release-controlling membrane (d) and filled into a two-piece, hard gelatin capsule.

		mg/capsule
(a)	Active Ingredient A	100
	Active Ingredient B	30
(b)	Microcrystalline Cellulose	60
(c)	Lactose B.P.	60
(d)	Ethyl Cellulose	6
		256

Example 3: Injectable Formulation

Formulation A

	<u>mg</u>
Active Ingredient A	100
Active Ingredient B	5
Hydrochloric Acid Solution 0.1 M or	
Sodium Hydroxide Solution 0.1 M q.s. to pH	4.0 to 7.0
Sterile water q.s. to	10 ml

The active ingredient is dissolved in most of the water (35°-40°C) and the pH adjusted to between 4.0 and 7.0 with the hydrochloric acid or the sodium

hydroxide as appropriate. The batch is then made up to volume with the water and filtered through a sterile micropore filter into a sterile 10 ml amber glass vial (type 1) and sealed with sterile closures and overseals.

Formulation B

Active Ingredient A 125 mg

Sterile, Pyrogen-free, pH 7 Phosphate

Buffer, q. s. to 25 ml

Example 4: Intramuscular injection

Active Ingredient A	100 mg
Active Ingredient B	30 mg
Benzyl Alcohol	0.067 g
Glycofurol 75	0.94 g
Water for injection q.s. to	3.00 ml

The active ingredient is dissolved in the glycofurol. The benzyl alcohol is then added and dissolved, and water added to 3 ml. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml amber glass vials (type 1).

Example 5: Syrup

100 mg
5 m g
0.6 g
0.85 g
0.0025 g
0.0125 ml
5.00 ml

5

The active ingredient is dissolved in a mixture of the glycerol and most of the purified water. An aqueous solution of the sodium benzoate is then added to the solution, followed by addition of the sorbital solution and finally the flavour. The volume is made up with purified water and mixed well.

Example 6: Suppository

	mg/capsule suppository
Active Ingredient A	100
Active Ingredient B	30
Hard Fat, B.P. (Witepsol H15 - Dynamit Nobel)	1770
	1900

One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a $200\mu\text{M}$ sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45°C , the remaining Witepsol H15 is added to the suspension and stirred to ensure a homogenous mix. The entire suspension is passed through a $250\mu\text{m}$ stainless steel screen and, with continuous stirring, is allowed to cool to 40°C . At a temperature of 38° C to 40°C , 2.02 g of the mixture is filled into suitable, 2 ml plastic moulds. The suppositories are allowed to cool to room temperature.

Example 7: Pessaries

	mg/pessary
Active Ingredient A	100
Active Ingredient B	5
Anhydrate Dextrose	160
Potato Starch	150
Magnesium Stearate	3
	440
	418

The above ingredients are mixed directly and pessaries prepared by direct compression of the resulting mixture.

Biological Data

Example 8.

The human hepatoblastoma cell line (Hep-G2-2.2.15) which constitutively produces infectious HBV was seeded into 96 well microtiter plates at a density of 5 x 10³ cells per well. These cells were treated with a combination of lamivudine and PMEA on triplicate plates. Culture media containing drugs was replenished every other day for 9 days, at which time supernatants were collected and analyzed for HBV content.

The lamivudine/PMEA combination was tested twice in triplicate in matrix fashion. Experiment 1 utilised a lamivudine range of 100 nM to 0.14 nM (3-fold dilutions in columns), and PMEA, 9-[(R)-2-(phosphonomethoxy)ethyl]adenine (adefovir), at concentrations of 1 μ M to 10 nM (3.16 fold dilutions in rows). Experiment 2 was performed with dilutions of Lamivudine ranging from 100nM to .045 nM (in 3-fold dilutions in columns), and a PMEA range of 5 μ M to 0.16 nM (3.16 fold dilutions in rows). Both drugs were diluted in a separate 96 well microtiter plate, and subsequently transferred onto plates containing the cell monolayers. Cells are grown in 150 μ I RPMI 1640 supplemented with 2 mM L-Glutamine and 10% fetal bovine serum. Prior to transfer of drug, 120 μ I of media was removed from the cells, leaving 30 μ I on the monolayers to prevent drying. 90 μ I of fresh media without drug was added, followed by the addition of 30 μ I of 5X drug dilutions. Lamivudine and PMEA were each tested on their respective plates individually at the same concentrations. Data were normalised to values obtained with non-drug treated cells, and expressed as a percent of control for

The method used for detection of HBV has been previously described (Jansen RW, Johnson LC, Averett, DR. High-Capacity in vitro assessment of antihepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chem 1993; 37 (3): 441-447.). Briefly, HBV detection was performed by "capturing" virus from supernatants on Anti-HBsAg coated plates, washing, denaturing to release HBV DNA, performing PCR with biotinylated primers, streptavidin capture of biotinylated PCR products with concomitant probe hybridization, addition of substrate, and reading optical densities of the colorimetric reaction. Dilutions of a standardized HBV-containing

35

15

20

25

30

analysis.

30

35

5

10

supernatant were included on every plate, and HBV DNA concentrations of test wells were calculated from this HBV standard curve. The useful range of detection is at least .045 to 45 fg of HBV DNA, where 30 copies of the genome can be reliably detected. Samples were tested in conjunction with both positive (.448 fg/ul plasmid DNA) and negative (RPMI medium supplemented with 2 mM L-Glutamine and 10% Fetal calf serum) controls.

The average IC50 and standard error of the IC50s for the triplicate plates were calculated using SAS nonlinear regression to fit data to the Hill equation for each concentration response curve. When only a single determination of an IC50 for a particular dose combination could be made, the average of the standard errors from adjacent concentrations was used to estimate the standard error. Fractional inhibitory concentrations (FIC50) were calculated for each combination and plotted using the isobologram representation (Berenbaum, M.C. (1985) The Expected Effect of a Combination of Agents: the General Solution, J. Theor. Biol. 114, 413-431). To assess statistical significance of synergy or antagonism, an unpaired t-test was used to compare each sum of paired FIC50 values with the theoretical value of 1. P values less than 0.05 were considered statistically significant. Comparison of P values between experiments must be interpreted with great care, as the experiments utilized different test concentration ranges (or ranges useable by the isobologram method). In some cases not all concentrations tested could support calculation of an IC50, since response was inhibited to a greater extent than 50 percent of control for all doses.

Figure 1 shows a single isobologram, produced by combining the data from both experiments, showing a statistically significant synergism.

Example 9

The IC₅₀ for PMEA was determined against wild type (WT) and lamivudine resistant HBV transiently expressed in a cell culture system as described below. HepG2 cells were transiently transfected with plasmid containing the HBV genome that had the wild type sequence or contained the following lamivudine resistant mutations in the reverse transcriptase gene; M552I, M552V, L528M, L528MM552V. It was previously determined that only the M552I and L528MM552V mutations were observed in HBV infected patients that developed

30

35

5

10

resistance to lamivudine therapy although the individual M552V and L528M mutations partially contributed to the loss in sensitivity of lamivudine against HBV replication in vitro (Allen MI, Deslauriers M, Andrews CW, Tipples GA. Walters KA, Tyrrell DLJ, Brown N for the Lamivudine Clinical Investigation Group, and Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. HEPATOLOGY 1998; 27:1670-1677). HepG2 cells were seeded into 96-well Costar plates at 6300 cells per well in 150 ul of HepG2 media (Dulbecco's Modified Eagle Medium (DMEM), containing 10% fetal bovine serum) and were incubated overnight at 37°C. For each transfected well, 75 ng of plasmid DNA and 0.5 µl of lipofectamine (Gibco) were incubated together for 30 minutes at room temperature in 12.5 µl of OptiMem (Gibco) prior to addition of DNA/lipofectamine mixture to cells. Each well was rinsed with 150 µl of unsupplemented DMEM. The DNA/lipofectamine mixture was added to each well in a total volume of 150 µl of OptiMem media. The cells were incubated with the DNA/lipofectamine solution for 5 hours at 37°C. After incubation, 150 µl of DMEM containing 20% serum was added to each well and plates were incubated overnight at 37°C. The media was replaced with 150 µl of HepG2 media only or media containing PMEA.

2.2.15 cells were seeded into 96-well Costar plates at 2250 cells per well in 150 µl of complete media (RPMl media containing 10% fetal bovine serum) and were incubated overnight at 37°C. The media was replaced with 150 µl of complete media only or media containing the desired concentration of PMEA.

Transfected cells, as well as 2.2.15 stable HBV-producer cells, were treated with control drug-free media or media containing PMEA every other day (day 1, 3, and 5). Final concentrations of PMEA for cell treatment were used at 25, 5, 1, 0.2, 0.04 μ M (for WT plasmid transfected cultures and control 2.2.15 cells) or 125, 25, 5, 1, 0.2 μ M (for all mutant plasmid transfected cultures).

HBV DNA levels were quantitated from media harvested from cells on day 7 using the methods described in Jansen RW, Johnson LC, Averett, DR. High-Capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chem 1993; 37 (3): 441-447. Further details are given in Example 8.

Cytotoxicity due to drug treatment was determined using the DNA stain Bisbenzimide (H33342 3HCl 4H₂0; Calbiochem Company, La Jolla CA). After the media was harvested, the cells were fixed with 70% ethanol for 30 minutes.

25

5

Cells were rinsed once with serum-free media and incubated with the DNA stain Bisbenzimide (H33342 3HCl 4H2O; Calbiochem Corporation, La Jolla CA) at 33 μg/ml for 1 hour at 37°C in serum-free medium. Fluorescent values per well were determined with a Millipore Cytofluor 2350 fluorescent plate reader (excitation, 355 nm; emission, 460 nm; arbitrary units). CC₅₀ values of each compound (concentration of compound that is cytotoxic for 50% of cells) were determined from the percent toxicity of each concentration of compound compared to untreated (no drug) cells using the method described below. Concentration response curves generated from each construct in the transient transfection experiment were fit to the Hill equation (y = $Vmax * (1 - (x^n/(k^n +$ $x^n))$ using non-linear regression to estimate the IC₅₀ (concentration of drug which inhibited HBV DNA production by 50%, compared to parallel drug-free cultures) and CC₅₀ of PMEA. The calculated IC₅₀ for each construct is shown with the 95% confidence bounds for the geometric means for n replicates. The program JMP (SAS, Cary NC) was used to perform student t-test evaluation of the data for determining statistically significant differences between treatment groups. The IC_{50} of PMEA obtained against WT HBV produced by the 2.2.15 cells (0.43 uM) was also comparable to the IC_{50} value (0.7 uM) using the same cell line. (Heijtink RA, De Wilde GA, Kruining J, Berk L, Balzarini J, De Clercq E, Holy A, Schalam SW. Inhibitory Effect of 9-(phosphonylmethoxyethyl)adenine(PMEA) on Human and Duck Hepatitis B Virus Infection. Antiviral Research 1993; 21 (2): 141-153).

Table 1. Comparison of IC₅₀s of PMEA between WT HBV and HBV containing lamivudine resistant associated mutations *in vitro*.

HBV construct	IC _{so} PMEA (95%CI)	x-fold change in IC ₅₀
2.2.15	0.43 uM (0.3 - 0.7 uM)	•
WT	0.53 uM (0.34 - 0.8 uM)	-
L528M/	1.3 uM (0.4 - 4.3 uM) ⁺	2.5
M552V		
M552I	7.5 uM (1.8 - 32 uM)*	14
M552V	9.8 uM (3.1 - 31 uM)**	18
L528M	0.87 uM (0.4 - 2.0 uM)	1.6

The state of the s

- * Statistically different IC $_{50}$ s of compound between mutant HBV and WT HBV, p < 0.05.
- $^{+}$ IC₅₀s are statistically different from each other, p < 0.05.
- For HepG2 cells, the cytotoxic IC_{50} for PMPA was greater than 125 uM, the cytotoxic IC_{50} for PMEA varied between 25 to 40 uM.

U3514-PCT

25 August 2000

1

Claims

5

10

25

30

- 1. A combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent, bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof wherein (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight.
- 2. A combination according to claim 1 wherein the ratio is in the range 25:1 to 15:1 by weight of active ingredients.
- 3. A combination according to any one of claims 1 to 3 for use in medicine.
- 4. A pharmaceutical formulation comprising a combination according to any one of claims 1 to 3 in association with one or more pharmaceutically acceptable carriers therefor.
- 5. A pharmaceutical formulation for use in the treatement of HBV comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof wherein (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight.
- 6. A formulation according to claims 4 or 5 in unit dosage form.
- 7. A formulation according to any one of claims 4 to 6 suitable for oral administration.

PU3514-PCT

5

10

30

35

25 August 2000

- 8. A formulation according to any one of claims 5 to 7 comprising between 25 to 150 mg of lamivudine and 5 to 60 mg adefovir dipivoxil.
- 9. A formulation according to claim 8 comprising 100 mg of lamivudine and 10 mg adefovir dipivoxil.
- 10. A method for the treatment of a mammal, including a human, with an HBV infection comprising administration of a therapeutically effective amount of a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof.
- 11. A method as claimed in claim 10 wherein the combination is as claimed in any of claims 1 to 3.
- 12. A method according to claim 10 or claim 11 wherein the combination is administered simultaneously.
- 13. A method according to claim 10 or claim 11 wherein the combination is administered sequentially.
- 25 14. A method according to claim 10 or claim 11 wherein the combination is administered as a single combined formulation.
 - 15. A method as claimed in any one of claims 10 to 14 for the treatment of an HBV infection resistant to nucleoside and/or non-nucleoside inhibitors of the replication of the hepatitis B virus
 - 16. Use of (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one in the manufacture of a medicament for administration either simultaneously or sequentially with bis(pivaloyloxymethyl)(9-[2-(phosphonomethoxy)ethyl]adenine, for the treatment of an HBV infection.

PU3514-PCT

5

10

25

30

35

25 August 2000

3

- 17. Use of bis(pivaloyloxymethyl)(9-[2-(phosphonomethoxy)ethyl]adenine in the manufacture of a medicament for administration either simultaneously or sequentially with (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)pyrimidin-2-one for the treatment of an HBV infection.
- 18. Use of a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof for the treatment of an HBV infection.
- Use of a combination as claimed in any one of claims 1 to 3 for the 19. treatment of an HBV infection.
- 20. Use of a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from either (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, or bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof wherein (2R,cis)-4-amino-1-(2hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight, for the treatment of an HBV infection resistant to nucleoside and/or nonnucleoside inhibitor.
- Use of a combination as claimed in any one of claims 1 to 3 for the 21. treatment of an HBV infection resistant to nucleoside and/or nonnucleoside inhibitor of the replication of the hepatitis B virus.
- 22. A patient pack comprising of at least one active ingredient selected from (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one, and bis(pivaloyloxymethyl)(9-[2-(phosphonomethoxy)ethyl]adenine and an information insert containing directions on the use of both active ingredients together in combination.

AMENDED SHEET

1/1

FIG. 1 COMBINATION ISOBOLOGRAM 1.2 LAMIVUDINE VS ADEFOVIR EXPT'L - ADDITIVE 1 0.8 FIC (ADEFOVIR) 0.6 0.4 0.2 0 0 0.2 0.4 0.6 8.0 1.2 FIC (LAMIVUDINE) **NET SUM** -3.102370207 SE 1.29895894 -2.388351257 t **AV DEV** -0.141016828 P (DEV) 0.013449974

APPI	BINED DECLAR LICATION WITH laration submitted with initial aration submitted after initial f	filing or	OF ATTORNE	Y PATENT	PU3514USW First Names Inventor. BROWN, Nathaniel A. Complete if known: App No.: Filing Date Group Art Unit:
	As below named	inventor. I here	by declare that:		
	My residence, post office	address and citiz	enship are as stated be	elow next to my name.	
				me is listed below) or an original, for claimed and for which a patent is so	
	the specification of which	(check only one	ANTIVIRAL COMe item below):	IBINATIONS	
[]is attached hereto. OR [x] was filed on 17 September 1999 as United States application Serial No or Application Number PCT/EP99/06886 filed and was amended on (MM/DD/YYYY) I hereby state that I have reviewed and understand the contents of the above-identified sy ecification as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 or inventor's certificate or 365(a) of any PCT international application which designated at least or United States of America, listed below and have also identified below, by checking the box, any for patent or inventor's certificate or of any PCT international application having a filing date before the which priority is claimed:				(if applicable) n, including the claims, CFR §1.56. clications(s) for patent e country other than the reign application for	
	r Foreign Application		Country	Foreign Filing Date	PRIORITY
1 000	Number (s)		CD	(MM/DD/YYYY))	CLAIMED
1. 9820 2.	J42U.Y		GB	09/18 /1998	X
3.					
4.					
5.	v claim the henefit under T	itle 35 United S	tates Code \$110(a) of	 any United States provisional appli	cation(s) listed helow
1 IICICU	Application No.	ine 55, Onited S.		ate (MM/DD/YYYY)	cation(s) fisted below.
1.					
2. 3.					
4.					

1
Q
1
100
Ñ
5, 5
7
122
Æ

ł	COMBINED DECLARATION FOR UTILITY or DESIGN PATENT APPLICATION WITH POWER OF ATTORNEY Continued ATTORNEY'S DOCKET NUMBER PU3514USW						
2	FULL NAME OF INVENTOR	FAMILY NAME RUBIN	FIRST GIVEN NAME Marc	SECOND GIVEN NAME/INITIAL			
(INVENTOR'S SIGNATURE						
0	RESIDENCE & CITIZENSHIP	CITY Chapel Hill	STATE OR FOREIGN COUNTRY NC	COUNTRY OF CITIZENSHIP US			
4	POST OFFICE ADDRESS	POST OFFICE ADDRESS Glaxo Wellcome Inc.	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709, US			
		Five Moore Drive, PO Box 13398					

As below named inventor. I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: ANTIVIRAL COMBINATIONS the specification of which (check only one item below): [] is attached hereto. OR Application Number PCT/EPP9/06886 filed and was amended on (MM/DD/YYYY)	APPLICATIO (X) Declaration submit	DECLARATION IN WITH POWER ted with initial filing or a dafter initial filing (surcharge	OF ATTORNEY	R DESIGN PATENT	ATTORNEY'S DOCKET PU3514USW First Names Inventor: BROWN, Nathaniel A. Complete if known: App No.: Filing Date
My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: ANTIVIRAL COMBINATIONS the specification of which (check only one item below): [] is attached hereto. OR [x] was filed on 17 September 1999 as United States application Serial No or PCT International Application Number PCT/EP99/06886 filed and was amended on (MM/DD/YYYY) (if applicable) I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56. I hereby claim foreign priority benefits under 35, U.S.C. §119 (a)-(d) or §365(b) of any foreign applications(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed: PRIOR FOREIGN AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119: Prior Foreign Application Country Foreign Filing Date PRIORITY Number (s) (MM/DD/YYYY) CLAIMED 1. 9820420.9 GB 09/18/1998 X 2. 3. 4.					Group Art Onit:
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: ANTIVIRAL COMBINATIONS the specification of which (check only one item below): [] is attached hereto. OR [x] was filed on 17 September 1999 as United States application Serial No or PCT International Application Number PCT/EP99/06886 filed, and was amended on (MM/DD/YYYY) (if applicable) I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56. I hereby claim foreign priority benefits under 35, U.S.C. §119 (a)-(d) or §365(b) of any foreign applications(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed: PRIOR FOREIGN AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119: Prior Foreign Application Number (s) GB O9/18/1998 X 2. 3. 4.	As	pelow named inventor. I he	ereby declare that:		<u> </u>
(if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: ANTIVIRAL COMBINATIONS the specification of which (check only one item below): [] lis attached hereto. OR [x] was filed on 17 September 1999 as United States application Serial No	My residence	e, post office address and ci	tizenship are as stated belo	ow next to my name.	Í
the specification of which (check only one item below): [] is attached hereto. OR [x] was filed on 17 September 1999 as United States application Serial No or PCT International Application Number PCT/EP99/06886 filed and was amended on (MM/DD/YYYY) (if applicable) I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56. I hereby claim foreign priority benefits under 35, U.S.C. §119 (a)-(d) or §365(b) of any foreign applications(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed: PRIOR FOREIGN AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119: Prior Foreign Application Number (s) GB O9/18 /1998 X 2. 3. 4.	(if plural nar				
I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56. I hereby claim foreign priority benefits under 35, U.S.C. §119 (a)-(d) or §365(b) of any foreign applications(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed: PRIOR FOREIGN AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119: Prior Foreign Application Number (s) GB O9/18/1998 X 2. 3. 4.				BINATIONS	
Prior Foreign Application Number (s) Country (MM/DD/YYYY) Foreign Filing Date (MM/DD/YYYY) PRIORITY CLAIMED 1. 9820420.9 GB 09/18 /1998 X 2. 3. 4. 4.	the specification of which (check only one item below): [] lis attached hereto. OR [x] was filed on 17 September 1999 as United States application Serial No. OR [x] was filed on 17 September 1999 as United States application Serial No. Or PCT International Application Number PCT/EP99/06886 filed and was amended on (MM/DD/YYYY) (if applicable) I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56. I hereby claim foreign priority benefits under 35, U.S.C. §119 (a)-(d) or §365(b) of any foreign applications(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on				
Number (s) (MM/DD/YYYY) CLAIMED 1. 9820420.9 GB 09/18 /1998 X 2. 3. 4. 4.					PRIORITY
2. 3. 4.	Number (s) (MM/DD/YYYY		(MM/DD/YYYY))		
3. 4.			X		
4.					
	4.				
5. Therefore the horizontal Title 25. United States Code \$110(x) St. United States Code States Cod					
I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below: Application No. Filing Date (MM/DD/YYYY)					
1.	1.		1 mig Date	(IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	
2.					
3. 4.					

COMBINED DECLARATION FOR UTILITY OR DESIGN PATENT					PU3514USW	
APPLICATION WITH POWER OF ATTORNEY					First Names Inventor: BROWN, Nathaniel A.	
(X) Dec	Complete if known: App No.:					
()Decla	ration submitted after initial	filing (surcharge re	quired 37CFR1.16(e))		Filing Date	
					Group Art Unit:	
	As below named	l inventor. I here	by declare that:		1	
' . 	My residence, post office	address and citiz	enship are as stated be	ow next to my name.		
				ne is listed below) or an original, aimed and for which a patent is s		
gartena,	the specification of which	h (check only one	ANTIVIRAL COMP item below):	BINATIONS		
	[]is attached hereto. OR					
		tember 1999 as	United States application	on Serial No or	PCT International	
	Application Number PC	T/EP99/06886fil	ed_and was amended o	n (MM/DD/YYYY)	(if applicable)	
m M	I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.					
# # # # # # # # # # # # # # # # # # #	I acknowledge the duty t	o disclose inform	ation which is material	to patentability as defined in 37 (CFR §1.56.	
on the test of the	[] is attached hereto. OR [x] was filed on 17 September 1999 as United States application Serial No					
PRIOR	FOREIGN AND ANY I	PRIORITY CLA	IMS UNDER 35 U.S.	C. 119:		
Prio	r Foreign Application Number (s)	(Country	Foreign Filing Date (MM/DD/YYYY))	PRIORITY CLAIMED	
1. 9820 2.	0420.9		GB	09/18 /1998	X	
3.						
4.						
5. I hereb	v claim the benefit under] Fitle 35, United St	tates Code 8119(e) of a	 ny United States provisional appl	ication(s) listed below:	
	Application No.			te (MM/DD/YYYY)		
1.						
2. 3.			 			
4.						
5.						

COMBINED DECLARATION FOR UTILITY or DESIGN PATENT APPLICATION WITH POWER OF ATTORNEY Continued

ATTORNEY'S DOCKET NUMBER

PU3514USW

I hereby claim the benefit under 35, U.S.C. §120 of any United States application or §365(c) of any PCT international application designating the United States of America that is listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States

	is material to pater	that is listed below and, insofar as the subje- ial application in the manner provided by the intability as defined in 37 C.F.R. §1 56 whice filing date of this application.	: iirsi naragranh (NT + (5 11 N (* 8112 1 20)	noveledge the duty to de	1
PRIO	R U.S. PARENT	APPLICATION or PCT PAREN	T APPI ICA	FION		
			AITLICA	1011	CTATTIC (CL. 1	
U.S	. Parent Application o	r PCT Parent Parent Fil	ing Data	DATENTED	STATUS (Check	
	Number	(MM/DD		PATENTED	PENDING	ABANDONED
		(1.1.1.2.2)				
POWEI the U.S.	R OF ATTORNEY: Patent and Trademark	As a named inventor, I hereby appoint the footnotes connected therewith (List name are	ollowing attorney d registration nu	(s) and/or agent(s) to pr nber)	osecute this application	and transact all business in
Ch Ka Ro	vid J. Levy arles E. Dadswell ren L. Prus bert H. Brink zabeth Selby	Reg No 35,851 Virg Reg No 39,337 Frank Reg. No. 36,094 Chris	es P. Riek guna C Bennett ak P Grassler stopher P. Roger e Ann Morgan	Reg. No. 39,009 Reg. No. 37,092 Reg. No. 31,164 Reg. No. 36,334 Reg. No. 38,181	Bonnie L Deppenbi John L. Lemanowic	rock Reg No. 28,209 z Reg. No. 37,380
Settel C	Correspondence to		10000000			
	David J. Levy, Pat				Direct Telephone C	alls to:
in the think then the	Global Intellectua	l Property Department	111111111111	W (Kare	n L. Prus
74 24	Glaxo Wellcome I	nc.	23	347	919-483-2192	
	Five Moore Drive Research Triangle	PO Box 13398	PATENT TRA	DEMARK OFFICE	ł	
	FULL NAME	the like so made are punishable by the tements may jeopardize the validity	of the applica	tion or any patent is	ssuing thereon.	
\ 24	OF INVENTOR	BROWN	Nathaniel		A.	/INITIAL
o I	INVENTOR'S	1 Pattlella				
a=	RESIDENCE &	CITY POWER OF SOM			x 3 20/	200 l
josta.	CITIZENSHIP	Cambridge	MA	DREIGN COUNTRY	COUNTRY OF CITIZEN	SHIP
	POST OFFICE	POST OFFICE ADDRESS	CITY	MD	STATE & ZIP CODE/CO	VIV.
1	ADDRESS	Glaxo Wellcome Inc.	Research	Triangle Park	NC 27709, US	UNTRY
		Five Moore Drive, PO Box 1339	8	g		
	FULL NAME	FAMILY NAME	FIRST GIVEN	NAME	SECOND GIVEN NAME	INITIAL
2	OF INVENTOR	CONDREAY	Lynn		D.	
	INVENTOR'S SIGNATURE					
0	RESIDENCE &	CITY	STATEOPE	DREIGN COUNTRY		
	CITIZENSHIP	Raleigh	NC	ALIGN COUNTRY	US UNTRY OF CITIZEN	SHIP
	POST OFFICE	POST OFFICE ADDRESS	CITY		STATE & ZIP CODE/CO	IINTRV
2	ADDRESS	Glaxo Wellcome Inc.	Research	Triangle Park	NC 27709, US	OILINI
		Five Moore Drive, PO Box 1339	8	Ç		
2	FULL NAME	FAMILY NAME GRAY	FIRST GIVEN NA	ME	SECOND GIVEN NAME	INITIAL
۷	OF INVENTOR INVENTOR'S	GRAI	Douglas		Fraser	
	SIGNATURE					
0	RESIDENCE &	CITY	STATE OR FORE	GN COUNTRY	COUNTRY OF CITIZEN	CITYD
	CITIZENSHIP	Greenford	GB		GB	omr
3	POST OFFICE	POST OFFICE ADDRESS	CITY		STATE & ZIP CODE/CO	UNTRY
J	ADDRESS	Glaxo Wellcome plc 891-995, Greenford Road	Greenford		Middlesex UB6	OHE, GB

COM PAT	ÍBINED DE ENT APPLI	CLARATION FOR UT CATION WITH POW	TILITY or DESIGN VER OF ATTORNEY Cor	ATTORNEY'S DOCKET NUMBER PU3514USW
2	FULL NAME OF INVENTOR	RUBIN	FIRST GIVEN NAME Marc	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE		,	
0	RESIDENCE & CITIZENSHIP	CITY Chapel Hill	STATE OR FOREIGN COUNTRY NC	COUNTRY OF CITIZENSHIP US
4	POST OFFICE ADDRESS	POST OFFICE ADDRESS Glaxo Wellcome Inc.	Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709, US
		Five Moore Drive, PO Box 13398		

COMBINED DECLARATION FOR UTILITY or DESIGN PATENT APPLICATION WITH POWER OF ATTORNEY Continued

ATTORNEY'S DOCKET NUMBER

PU3514USW

I hereby claim the binefit under 35, U.S.C. §120 of any United States application or §365(c) of any PCT international application designating the United States of America that is listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States

PRIOR U.S. PARENT APPLICATION or PCT PARENT APPLICATION U.S. Parent Application or PCT Parent Number U.S. Parent Application or PCT Parent Number U.S. Parent Application or PCT Parent Number PATENTED PENDING ABANDON ABANDON ABANDON ABANDON ABANDON PATENTED PENDING ABANDON ABANDON ABANDON ABANDON ABANDON PENDING ABANDON ABANDON ABANDON ABANDON ABANDON PENDING ABANDON PATENTED PENDING ABANDON			ling date of this application					
U.S. Parent Application or PCT Parent Number PATENTED PENDING ABANDON (MM/DD/YYYY) POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all but the U.S. Patent and Trademark Office connected therewith (List name and registration number) David J. Levy Reg. No. 27.655. Charles E. Dedowell Reg. No. 27.655. Ref. No. 27.655. Lorie Am Morgan Direct Telephone Calls to: Direct Telephone Calls to: Direct Telephone Calls to: March L. Prus 919-483-2192 Direct Telephone Calls to: Res. No. 28.256. Thereby declare that all statements made herein of my own knowledge are true and that all statements made on inform and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements mady jeopardize the validity of the application or any patent issuing thereon. PEVENTOR'S RESENDENCE & CITY	PRIOR	R U.S. PARENT A	APPLICATION or PC	T PARENT A	PPLICATION	<u> </u>	CTATIC (Chools	
Number (MM/DD/YYYY) POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and trainsact all but he U.S. Patent and Trademark Office connected therewith (List name and registration number) David J. Levy Reg. No. 22,525. David J. Levy Reg. No. 23,585. Karen L. Prus Reg. No. 35,295. Karen L. Prus Robert II. Brink Reg. No. 36,094. Charles E. Dadswell Reg. No. 35,295. Karen L. Prus Robert II. Brink Reg. No. 36,094. Christopher P. Rogens Reg. No. 36,0314. Lorie Am Morgan Reg. No. 31,104 David J. Levy, Patent Counsel Global Intellectual Property Department Globa	110	Donant Application on	DCT Parant	Donant Falin o F) ata	DATEMED		
Buyld J. Levy Reg. No. 27.655. James P. Riek Reg. No. 20.002 Charles E. Dadswell Reg. No. 35.851 Karen L. Prus Reg. No. 30.337. Frank P. Grassler Reg. No. 31.002 Karen L. Prus Reg. No. 30.337. Frank P. Grassler Reg. No. 31.004 Elizabeth Selby Reg. No. 38.298 Loric Ann Morgan Reg. No. 38.181 Sered Correspondence to: David J. Levy, Patent Counset Global Intellectual Property Department Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 I hereby declare that all statements made herein of my own knowledge are true and that all statements made on inform and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under U.S. C. 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon. FULL NAME OF INVENTOR BROWN I FULL NAME OF INVENTOR BROWN I ADDRESS Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 EULI NAME OF INVENTOR GLAXORES OF RESIDENCE & CITY ADDRESS GLAXORES FULL NAME OF INVENTOR CONDREAY FULL NAME OF INVENTOR CONDREAY Research Triangle Park FULL NAME OF INVENTOR CONDREAY POST OFFICE ADDRESS GLAXORES GLAXORES CITY ADDRESS GLAXORES GLAXORES CITY RESECUTOR FOREIGN COUNTRY RESEarch Triangle Park FULL NAME OF INVENTOR CONDREAY FULL NAME OF INVENTOR CONDREAY POST OFFICE ADDRESS GLAXORES GLAXORES CITY RESECUTOR FOREIGN COUNTRY RESEarch Triangle Park FULL NAME OF INVENTOR CONDREAY POST OFFICE ADDRESS FIRST GIVEN NAME SECOND GIVEN NAME/INITIAL A. SECOND GIVEN NAME/INITIAL D. FULL NAME FIRST GIVEN NAME FULL NAME FIRST GIVEN NAME FIRST GIVEN NAME FIRST GIVEN NAME FULL NAME FIRST GIVEN NAME FULL NAME FULL NAME FIRST	U.S.		PCT Parent			PATENTED	PENDING	ABANDONED
The U.S. Patent and Trademark Office connected threwith (List name and registration number) David J. Levy Reg. No. 27.65.5. David J. Levy Reg. No. 32.58.51 Karen L. Prus Reg. No. 32.33.7 Frank P. Grassler Reg. No. 31.09.02 Christopher P. Rogers Reg. No. 36.34 Elizabeth Selby Reg. No. 38.298 Lorie Ann Morgan Reg. No. 38.181 Direct Telephone Calls to: David J. Levy, Patent Counsel Global Intellectual Property Department Glaxa Wellcome Inc. Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 Thereby declare that all statements made herein of my own knowledge are true and that all statements made on inform and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under U.S. C. 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon. FULL NAME FAMILY NAME RESEARCH TRIANGE PARK RESEARCH TRI								}
David J. Levy Reg. No. 27.655. Charles E. Dadswell Reg. No. 25.5851 Reg. No. 23.317 Robert H. Brink Reg. No. 36.094 Reg. No. 33.317 Robert H. Brink Reg. No. 36.094 Reg. No. 38.298 Lorie Ann Morgan Reg. No. 36.094 Lorie Ann Morgan Reg. No. 36.3181 Direct Telephone Calls to: David J. Levy, Patent Counsel Global Intellectual Property Department Reg. No. 33,334 Direct Telephone Calls to: Direct Telephone Calls to: Exercise Reg. No. 36,38181 Direct Telephone Calls to: Reg. No. 38,38181 Direct Telephone Calls to: Reg. No. 36,38181 Direct Telephone Calls t							secute this application	and transact all busines
Charles E. Dadswell Karen L. Prus Robert H. Brink Reg. No. 32,317 Robert H. Brink Reg. No. 32,317 Robert H. Brink Reg. No. 32,328 Reg. No. 32,328 Reg. No. 36,094 Reg. No. 38,298 Reg. No. 38,181 Direct Telephone Calls to: David J. Levy, Patent Counset Global Intellectual Property Department Global Intellectual Property Depa	ne U.S. I	Patent and Trademark	Office connected therewith	(List name and reg	gistration number)			
David J. Levy, Patent Counsel Global intellectual Property Department Global mellectual Property Department Government Material Research Triangle Park NC 27709, US FULL NAME OF INVENTOR'S SIGNATURE FIRE GIVEN NAME OF INVENTOR'S Global Mellectual Property Department Government MA A. FIRST GIVEN NAME SECOND GIVEN NAME/NAME SECOND GIVEN NAME/NITIAL D. D. FULL NAME OF INVENTOR'S SIGNATURE FULL NAME OF INVENTOR'S Global Mellectual Property Additional Property of Country Of Citizenship CITIZENSHip FOST OFFICE FIVE Moore Drive, PO Box 13398 FIRST GIVEN NAME FIRST GIVEN NAME FIRST GIVEN NAME FIRST GIVEN NAME SECOND GIVEN NAME/NITIAL D. FIRST GIVEN NAME SECOND GIVEN NAME/NITIAL D. STATE & ZIP CODECOUNTRY OUTSTEENSHIP COUNTRY OF CITIZENSHIP FIRST GIVEN NAME SECOND GIVEN NAME/NITIAL D. FIRST GIVEN NAME SECOND GIVEN NAME/NITIAL	Cha Kar Rol	arles E. Dadswell ren L. Prus bert H. Brink	Reg. No. 35,851 Reg. No. 39,337 Reg. No 36,094	Virginia Frank P Christop	C. Bennett R Grassler R her P Rogers F	Reg No. 37,092 Reg No. 31,164 Reg. No. 36,334		
David J. Levy, Patent Comised Global Intellectual Property Department Glaxo Wellcome Inc.	end C	orrespondence to:	A STATE OF THE STA	<u> </u>			Direct Telephone C	Calls to:
Thereby declare that all statements made herein of my own knowledge are true and that all statements made on inform and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon. FULL NAME	47/0	David J. Levy, Pate Global Intellectual Glaxo Wellcome In Five Moore Drive,	ent Counsel Property Department ic. PO Box 13398					
CITIZENSHIP POST OFFICE POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FAMILY NAME OF INVENTOR'S SIGNATURE POST OFFICE ADDRESS CITY Research Triangle Park FAMILY NAME CONDREAY Lynn D. SECOND GIVEN NAME/INITIAL Lynn D. SPATEOR FOREIGN COUNTRY COUNTRY OF CHIZENSHIP POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FULL NAME OF INVENTOR'S Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FULL NAME OF INVENTOR'S SIGNATURE OF RESIDENCE & CITY STATE & ZIP CODE/COUNTRY COUNTRY OF CHIZENSHIP COUNTRY COUNTRY OF CHIZENSHIP COUNTRY COUNTRY OF CHIZENSHIP COUNTRY CO	The state of the s	and belief are be statements and t	elieved to be true; and for the like so made are pun	urther that these hishable by fine	e statements we or imprisonme	ere made with th ent, or both, und	ne knowledge that eer 18 U.S.C. 1001.	willful false
CITIZENSHIP POST OFFICE POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FAMILY NAME OF INVENTOR'S SIGNATURE POST OFFICE ADDRESS CITY Research Triangle Park FAMILY NAME CONDREAY Lynn D. SECOND GIVEN NAME/INITIAL Lynn D. SPATEOR FOREIGN COUNTRY COUNTRY OF CHIZENSHIP POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FULL NAME OF INVENTOR'S Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FULL NAME OF INVENTOR'S SIGNATURE OF RESIDENCE & CITY STATE & ZIP CODE/COUNTRY COUNTRY OF CHIZENSHIP COUNTRY COUNTRY OF CHIZENSHIP COUNTRY COUNTRY OF CHIZENSHIP COUNTRY CO	Marie Trans III. (1997) 1991	and belief are be statements and t willful false stat	elieved to be true; and fi he like so made are pun ements may jeopardize	urther that these hishable by fine the validity of	e statements we or imprisonme the application	ere made with th ent, or both, und	ne knowledge that er 18 U.S.C. 1001 suing thereon.	willful false , and that such
POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FULL NAME OF INVENTOR NESIDENCE & CITY Research Triangle Park FOUNDREAY POST OFFICE RESIDENCE & CITY RESEARCH Triangle Park FIRST GIVEN NAME Lynn D. SECOND GIVEN NAME/INITIAL D. SECOND GIVEN NAME/INITIAL D. SECOND GIVEN NAME/INITIAL D. STATE & ZIP CODE/COUNTRY NC 27709, US SIGNATURE POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FULL NAME OF INVENTOR'S SIGNATURE POST OFFICE INVENTOR'S SIGNATURE RESIDENCE & CITY FULL NAME OF INVENTOR GRAY FAMILY NAME OF INVENTOR'S SIGNATURE RESIDENCE & CITY Grave STATE & ZIP CODE/COUNTRY NC 27709, US FIRST GIVEN NAME Douglas FIRST GIVEN NAME FAMILY NAME OF INVENTOR'S SIGNATURE ORAY POST OFFICE POST OFFICE POST OFFICE ADDRESS CITY STATE OR FOREIGN COUNTRY GRAY STATE & ZIP CODE/COUNTRY NC 27709, US STATE & ZIP CODE/COUNTRY COUNTRY OF CITIZENSHIP GRAY COUNTRY OF CITIZENSHIP GRAY STATE & ZIP CODE/COUNTRY STATE & ZIP CODE/COUNTRY COUNTRY OF CITIZENSHIP GRAY STATE & ZIP CODE/COUNTRY	Mary III Company	and belief are be statements and t willful false stat FULL NAME OF INVENTOR INVENTOR'S	elieved to be true; and fi he like so made are pun ements may jeopardize	urther that these hishable by fine the validity of	e statements we or imprisonme the application	ere made with th ent, or both, und	ne knowledge that er 18 U.S.C. 1001 suing thereon.	willful false , and that such
ADDRESS Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FULL NAME OF INVENTOR OF INVENTOR'S SIGNATURE POST OFFICE ADDRESS FULL NAME OF INVENTOR'S SIGNATURE POST OFFICE ADDRESS FIRST GIVEN NAME Lynn D. FIRST GIVEN NAME Lynn D. SECOND GIVEN NAME/INITIAL D. SAME OF COUNTRY OF CHIZENSHIP US STATE & ZIP CODE/COUNTRY NC 27709, US FULL NAME OF INVENTOR'S SIGNATURE POST OFFICE OF INVENTOR'S SIGNATURE RESIDENCE & CITY OF INVENTOR'S SIGNATURE OF RESIDENCE & CITY STATE OF FOREIGN COUNTRY Research Triangle Park FIRST GIVEN NAME Douglas FIRST GIVEN NAME FRAMILY NAME FRAMILY NAME OF INVENTOR'S SIGNATURE RESIDENCE & CITY GRAY FOREIGN COUNTRY OF CHIZENSHIP OUTLIERSHIP GRAY FOREIGN COUNTRY COUNTRY OF CHIZENSHIP OUTLIERSHIP OUTLIERSHIP GRAY FRAMILY NAME OF COUNTRY OF CHIZENSHIP GRAY FRAMILY NAME OF COUNTRY OF CHIZENSHIP GRAY FRAMILY NAME OF COUNTRY OF CHIZENSHIP GRAY STATE & ZIP CODE/COUNTRY STATE & ZIP CODE/COUNTRY STATE & ZIP CODE/COUNTRY STATE & ZIP CODE/COUNTRY STATE & ZIP CODE/COUNTRY STATE & ZIP CODE/COUNTRY STATE & ZIP CODE/COUNTRY	The second state of the second	and belief are be statements and t willful false stat FULL NAME OF INVENTOR INVENTOR'S SIGNATURE RESIDENCE &	elieved to be true; and fi he like so made are pun ements may jeopardize FAMILY NAME BROWN	urther that these hishable by fine the validity of	e statements we or imprisonme the application inst given name Nathaniel	ere made with thent, or both, und	ne knowledge that er 18 U.S.C. 1001 suing thereon. SECOND GIVEN NAM A. COUNTRY OF CITIZE	willful false , and that such
FULL NAME OF INVENTOR'S SIGNATURE OF RESIDENCE & CITY Raleigh POST OFFICE FULL NAME OF INVENTOR'S SIGNATURE OF RESIDENCE & CITY RALEIGH POST OFFICE OF RESIDENCE & CITY RESEARCH Triangle Park FAMILY NAME OF INVENTOR'S SIGNATURE OF RESIDENCE & CITY FAMILY NAME OF INVENTOR'S SIGNATURE OF RESIDENCE & CITY FAMILY NAME OF INVENTOR'S SIGNATURE OF RESIDENCE & CITY STATE OR FOREIGN COUNTRY OF CITIZENSHIP OF RESIDENCE & CITY STATE OR FOREIGN COUNTRY OF CITIZENSHIP OF RESIDENCE & CITY STATE OR FOREIGN COUNTRY OF CITIZENSHIP OF RESIDENCE & CITY STATE OR FOREIGN COUNTRY OR CITIZENSHIP OF RESIDENCE & CITY STATE OR FOREIGN COUNTRY OF CITIZENSHIP OF STATE & ZIP CODE/COUNTRY OF CITIZENSHIP OF STATE & ZIP CODE/COUNTRY		and belief are be statements and t willful false stat willful false stat FULL NAME OF INVENTOR INVENTOR'S SIGNATURE RESIDENCE & CITIZENSHIP	elieved to be true; and fi the like so made are pun tements may jeopardize FAMILY NAME BROWN	urther that these hishable by fine the validity of	e statements we or imprisonme the application inst given name Nathaniel STATE OR FOREIGMA	ere made with thent, or both, und	e knowledge that er 18 U.S.C. 1001 suing thereon. SECOND GIVEN NAM A. COUNTRY OF CITIZE US	willful false , and that such E/INITIAL INSHIP
INVENTOR'S SIGNATURE RESIDENCE & CITY Raleigh POST OFFICE ADDRESS FULL NAME OF INVENTOR'S SIGNATURE OF INVENTOR'S SIGNATURE Raleigh POST OFFICE POST OFFICE ADDRESS FIRST GIVEN NAME OF INVENTOR'S SIGNATURE OF RESIDENCE & CITY RESCARCH Triangle Park FAMILY NAME OF INVENTOR'S SIGNATURE ORAY ORAY STATE OR FOREIGN COUNTRY NC 27709, US FIRST GIVEN NAME Douglas Fraser ORAY OF INVENTOR'S SIGNATURE ORAY ORAY ORESIDENCE & CITY COUNTRY OF CITIZENSHIP ORBORITATION OF CITIZENSHIP OR COUNTRY OF CITIZENSHIP ORBORITATION OR FOREIGN COUNTRY COUNTRY OF CITIZENSHIP ORBORITATION OR FOREIGN COUNTRY OR COUNTRY OF CITIZENSHIP ORBORITATION OR STATE OR FOREIGN COUNTRY OR COUNTRY OF CITIZENSHIP ORBORITATION OR STATE OR FOREIGN COUNTRY OR STATE & ZIP CODE/COUNTRY	The first team of the team of	and belief are be statements and t willful false stat willful false stat FULL NAME OF INVENTOR INVENTOR'S SIGNATURE RESIDENCE & CITIZENSHIP POST OFFICE	elieved to be true; and fi the like so made are pun tements may jeopardize FAMILY NAME BROWN CITY Cambridge POST OFFICE ADDRESS Glaxo Wellcome Inc	urther that these ishable by fine the validity of	e statements we or imprisonme the application inst given name Nathaniel STATE OR FOREIGMA CITY	ere made with thent, or both, und or any patent is	e knowledge that er 18 U.S.C. 1001 suing thereon. SECOND GIVEN NAM A. COUNTRY OF CITIZE US STATE & ZIP CODE/C	willful false , and that such E/INITIAL ENSHIP
SIGNATURE RESIDENCE & CITY Raleigh POST OFFICE ADDRESS FULL NAME OF INVENTOR'S SIGNATURE RESIDENCE & CITY RAMILY NAME OF INVENTOR'S SIGNATURE RESIDENCE & CITY STATE & ZIP CODE/COUNTRY NC 27709, US FIRST GIVEN NAME Douglas FIRST GIVEN NAME FRAMILY NAME OF INVENTOR'S SIGNATURE RESIDENCE & CITY CITIZENSHIP RESIDENCE & CITY CITIZENSHIP OF RESIDENCE & CITY CITY OF RESIDENCE & CITY OF RESIDE	There is a second of the secon	and belief are be statements and t willful false stat willful false stat FULL NAME OF INVENTOR INVENTOR'S SIGNATURE RESIDENCE & CITIZENSHIP POST OFFICE ADDRESS	chieved to be true; and find like so made are puntements may jeopardize FAMILY NAME BROWN CITY Cambridge POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, P	urther that these ishable by fine the validity of	e statements we or imprisonme the application inst given name Nathaniel STATE OR FOREIGMA CITY Research Tr	ere made with the ent, or both, und or any patent is	country of citize US STATE & ZIP CODE/C NC 27709, US	willful false , and that such EINITIAL INSHIP
CITIZENSHIP POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FULL NAME OF INVENTOR'S SIGNATURE RESIDENCE & CITY Research Triangle Park FIRST GIVEN NAME OF INVENTOR'S SIGNATURE RESIDENCE & CITY STATE & ZIP CODE/COUNTRY NC 27709, US FIRST GIVEN NAME Douglas FIRST GIVEN NAME FRAMILY NAME GRAY STATE OR FOREIGN COUNTRY STATE & ZIP CODE/COUNTRY NC 27709, US SECOND GIVEN NAME/INITIAL Fraser COUNTRY OF CITIZENSHIP GRAY COUNTRY OF CITIZENSHIP GB GB STATE & ZIP CODE/COUNTRY STATE OR FOREIGN COUNTRY STATE & ZIP CODE/COUNTRY STATE & ZIP CODE/COUNTRY	There is a second of the secon	and belief are be statements and t willful false stat willful false stat FULL NAME OF INVENTOR'S SIGNATURE RESIDENCE & CITIZENSHIP POST OFFICE ADDRESS FULL NAME OF INVENTOR	chieved to be true; and find like so made are pure tements may jeopardize promise properties and find like so made are pure tements may jeopardize promise pro	urther that these hishable by fine the validity of F	e statements we or imprisonme the application inst given name Nathaniel STATE OR FOREIGMA CITY Research Tr	ere made with the ent, or both, und or any patent is	country of citize US STATE & ZIP CODE/C NC 27709, US	willful false , and that such EINITIAL INSHIP
POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 FULL NAME OF INVENTOR'S SIGNATURE RESIDENCE & CITY Research Triangle Park FAMILY NAME Douglas FIRST GIVEN NAME Douglas FIRST GIVEN NAME FRAMILY NAME FRAMILY NAME GRAY Douglas SECOND GIVEN NAME/INITIAL Fraser COUNTRY OF CITIZENSHIP GRESIDENCE & CITY STATE OR FOREIGN COUNTRY GB GB STATE & ZIP CODE/COUNTRY STATE & ZIP CODE/COUNTRY STATE & ZIP CODE/COUNTRY	There is a second of the secon	and belief are be statements and t willful false stat willful false stat willful false stat FULL NAME OF INVENTOR'S SIGNATURE RESIDENCE & CITIZENSHIP POST OFFICE ADDRESS FULL NAME OF INVENTOR INVENTOR'S	chieved to be true; and find like so made are pure tements may jeopardize promise properties and find like so made are pure tements may jeopardize promise pro	urther that these hishable by fine the validity of F	e statements we or imprisonme the application instruction instruction instruction instruction instruction instruction instruction instruction in the imprisonment in t	ere made with the ent, or both, und or any patent is GN COUNTRY	country of citize US State & Zip code/C NC 27709, US Second Given Nam D.	willful false , and that such E/INITIAL E/INITIAL E/INITIAL
Five Moore Drive, PO Box 13398 FULL NAME OF INVENTOR INVENTOR'S SIGNATURE RESIDENCE & CITY CITIZENSHIP POST OFFICE POST OFFICE Five Moore Drive, PO Box 13398 FIRST GIVEN NAME FIRST GIVEN NA	the state of the s	and belief are be statements and t willful false statements and t willful false statements and tender of inventor inventors signature address full name of inventor inventor inventor inventor signature residence & residence and	clieved to be true; and find like so made are puntements may jeopardize FAMILY NAME BROWN CITY Cambridge POST OFFICE ADDRESS Glaxo Wellcome Inc Five Moore Drive, P FAMILY NAME CONDREAY Jym.	urther that these hishable by fine the validity of F	e statements we or imprisonme the application inst given name vathaniel STATE OR FOREM MA CITY Research Tr FIRST GIVEN NAM Lynn	ere made with the ent, or both, und or any patent is GN COUNTRY	country of citize State & Zip Code/C NC 27709, US Second Given Nam A. COUNTRY OF CITIZE US STATE & Zip CODE/C NC 27709, US Second Given Nam D. 2//3/0/ COUNTRY OF CITIZE	willful false , and that such E/INITIAL E/INITIAL E/INITIAL
FULL NAME FAMILY NAME FIRST GIVEN NAME SECOND GIVEN NAME/INITIAL Fraser INVENTOR'S SIGNATURE RESIDENCE & CITY STATE OR FOREIGN COUNTRY COUNTRY OF CITIZENSHIP GRAY POST OFFICE POST OFFICE ADDRESS CITY STATE & ZIP CODE/COUNTRY	Harry of H. Carlot Market and L. Carlot Market and	and belief are be statements and t willful false stat willful false stat willful false stat full NAME OF INVENTOR INVENTOR'S SIGNATURE RESIDENCE & CITIZENSHIP POST OFFICE INVENTOR INVENTOR'S SIGNATURE RESIDENCE & CITIZENSHIP POST OFFICE	clieved to be true; and find like so made are puntements may jeopardize FAMILY NAME BROWN CITY Cambridge POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, P FAMILY NAME CONDREAY CITY Raleigh POST OFFICE ADDRESS	in the that these his hable by fine the validity of F	e statements we or imprisonme the application like applic	ere made with the ent, or both, und or any patent is GN COUNTRY GN COUNTRY GN COUNTRY	country of citize US Second Given Nam A. COUNTRY OF CITIZE US STATE & ZIP CODE/C NC 27709, US SECOND GIVEN NAM D. 2//3/0/ COUNTRY OF CITIZE US STATE & ZIP CODE/C STATE & ZIP CODE/C	willful false , and that such E/INITIAL E/INITIAL E/INITIAL E/INITIAL
INVENTOR'S SIGNATURE O RESIDENCE & CITY CITIZENSHIP Greenford GB POST OFFICE POST OFFICE ADDRESS INVENTOR'S STATE OR FOREIGN COUNTRY COUNTRY OF CITIZENSHIP GB STATE & ZIP CODE/COUNTRY	Harry of H. Carlot Market and L. Carlot Market and	and belief are be statements and t willful false stat willful false stat willful false stat full NAME OF INVENTOR INVENTOR'S SIGNATURE RESIDENCE & CITIZENSHIP POST OFFICE INVENTOR INVENTOR'S SIGNATURE RESIDENCE & CITIZENSHIP POST OFFICE	clieved to be true; and find like so made are puntements may jeopardize FAMILY NAME BROWN CITY Cambridge POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, P. FAMILY NAME CONDREAY CITY Raleigh POST OFFICE ADDRESS Glaxo Wellcome Inc.	the validity of F N O Box 13398	e statements we or imprisonme the application like applic	ere made with the ent, or both, und or any patent is GN COUNTRY GN COUNTRY GN COUNTRY	country of citize US Second Given Nam A. COUNTRY OF CITIZE US STATE & ZIP CODE/C NC 27709, US SECOND GIVEN NAM D. 2//3/0/ COUNTRY OF CITIZE US STATE & ZIP CODE/C STATE & ZIP CODE/C	willful false , and that such E/INITIAL E/INITIAL E/INITIAL E/INITIAL
O RESIDENCE & CITY CITIZENSHIP Greenford GB COUNTRY POST OFFICE POST OFFICE ADDRESS CITY STATE OR FOREIGN COUNTRY GB COUNTRY OF CITIZENSHIP GB STATE & ZIP CODE/COUNTRY	Harm of H. Wang and H. Wang an	and belief are be statements and t willful false stat willful false stat willful false stat full NAME OF INVENTOR INVENTOR'S SIGNATURE RESIDENCE & CITIZENSHIP POST OFFICE ADDRESS SIGNATURE RESIDENCE & CITIZENSHIP POST OFFICE ADDRESS FULL NAME	clieved to be true; and find like so made are pure tements may jeopardize promise properties of the like so made are pure tements may jeopardize promise properties properties promise properties promise promise promise promise promise promise promise properties promise p	conditions that these the validity of the vali	e statements we or imprisonme the application the application inst given name nathaniel STATE OR FOREM MA CITY Research Tr FIRST GIVEN NAM Lynn STATE OR FOREM NAME TRST GIVEN NAME	ere made with the ent, or both, und or any patent is GN COUNTRY GN COUNTRY GN COUNTRY	country of citize US SECOND GIVEN NAM A. COUNTRY OF CITIZE US STATE & ZIP CODE/C NC 27709, US STATE & ZIP CODE/C US SECOND GIVEN NAM	willful false , and that such E/INITIAL E/INITIAL E/INITIAL E/INITIAL E/INITIAL E/INITIAL
POST OFFICE POST OFFICE ADDRESS CITY STATE & ZIP CODE/COUNTRY	Harm of H. Wang and H. Wang an	and belief are be statements and the willful false state willful false state willful false state of inventor inventor's signature residence address full name of inventor inventor inventor inventor inventor residence address residence address residence address full name of inventor inventor's	clieved to be true; and find like so made are pure tements may jeopardize promise properties of the like so made are pure tements may jeopardize promise properties properties promise properties promise promise promise promise promise promise promise properties promise p	conditions that these the validity of the vali	e statements we or imprisonme the application the application inst given name nathaniel STATE OR FOREM MA CITY Research Tr FIRST GIVEN NAM Lynn STATE OR FOREM NAME TRST GIVEN NAME	ere made with the ent, or both, und or any patent is GN COUNTRY GN COUNTRY GN COUNTRY	country of citize US SECOND GIVEN NAM A. COUNTRY OF CITIZE US STATE & ZIP CODE/C NC 27709, US STATE & ZIP CODE/C US SECOND GIVEN NAM	willful false , and that such E/INITIAL E/INITIAL E/INITIAL E/INITIAL E/INITIAL E/INITIAL
	1 2 2	and belief are be statements and the willful false state willful false state willful false state of inventor inventors signature residence address full name of inventor inventors signature residence address full name of inventor inventors address full name of inventor residence are signature residence are stated in the stated inventor inventor inventor inventor are stated in the stated in the stated inventor inventor inventor inventor are stated in the stated inventor inventor inventor inventor are stated in the stated in the stated inventor inventor inventor inventor inventor inventor are stated in the stated in t	clieved to be true; and find like so made are puntements may jeopardize FAMILY NAME BROWN CITY Cambridge POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, P FAMILY NAME CONDREAY CITY Raleigh POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, P FAMILY NAME GRAY CITY	control of the validity of the	e statements we or imprisonme the application the application at the application with a state or foreign the state	ere made with the ent, or both, und or any patent is GN COUNTRY riangle Park GN COUNTRY riangle Park	country of citize US SECOND GIVEN NAM A. COUNTRY OF CITIZE US STATE & ZIP CODE/C NC 27709, US SECOND GIVEN NAM D. Z//Z/O/ COUNTRY OF CITIZE US STATE & ZIP CODE/C NC 27709, US SECOND GIVEN NAM Fraser	willful false , and that such E/INITIAL E/INITIAL E/INITIAL EVENITIAL EVENITIAL
3 ADDRESS Glaxo Wellcome plc Greenford Middlesex UB6 0HE, GB	1 2 2	and belief are be statements and the willful false state willful false state willful false state of inventor inventors. Signature address full name of inventor inventor. Signature residence address full name of inventor. Signature residence accitizenship residence accitizenship.	clieved to be true; and find like so made are puntements may jeopardize FAMILY NAME BROWN CITY Cambridge POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, P FAMILY NAME CONDREAY CITY Raleigh POST OFFICE ADDRESS Glaxo Wellcome Inc. Five Moore Drive, P FAMILY NAME GRAY CITY Greenford	control of the validity of the	e statements we or imprisonme the application the application at the application with a state or foreign MA. CITY Research Tr FIRST GIVEN NAME Lynn STATE OR FOREIGN CITY Research Tr IRST GIVEN NAME Ouglas TATE OR FOREIGN CITY TRATE OR FOREIGN CITY TRATE OR FOREIGN CITY TATE O	ere made with the ent, or both, und or any patent is GN COUNTRY riangle Park GN COUNTRY riangle Park	country of citize US SECOND GIVEN NAM A. COUNTRY OF CITIZE US STATE & ZIP CODE/C NC 27709, US SECOND GIVEN NAM D. Z//Z/O/ COUNTRY OF CITIZE US STATE & ZIP CODE/C NC 27709, US SECOND GIVEN NAM Fraser	willful false , and that such E/INITIAL ENSHIP E/INITIAL ENSHIP EVINITIAL ENSHIP

COMBINED DECLARATION FOR UTILITY or DESIGN PATENT APPLICATION WITH POWER OF ATTORNEY Continued

ATTORNEY'S DOCKET NUMBER

PU3514USW

I hereby claim the benefit under 35, U.S.C. §120 of any United States application or §365(c) of any PCT international application designating the United States of America that is listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

	PCT international f	ntability as defined in 37 C.F.R. §1.56 which filing date of this application:	became available between	the filing date o	f the prior application(s) and the national or
PRIO	R U.S. PARENT	APPLICATION or PCT PARENT	T APPLICATION			
					STATUS (Check of	200)
U.S. Parent Application or PCT Parent Number			Parent Filing Date PAT		PENDING PENDING	ABANDONED
		(MINDO)				
POWER	R OF ATTORNEY:	As a named inventor, I hereby appoint the fol	lowing attorney(s) and/or a	agent(s) to prose	cute this application and	trancact all business
in the U.	S. Patent and Tradema	ark Office connected therewith. (List name a	nd registration number)	(a) at proce	oute and approaction and	a transact an ousmess
	David J. Levy Reg. No. 27,655		James P. Riek Reg. No 39,009		Bonnie L Deppenbrock Reg. No. 28,209	
	arles E. Dadswell ren L. Prus	Reg. No. 35,851 Virgin		lo. 37,092	John L. Lemanowicz	Reg. No. 37,380
	bert H. Brink			Vo. 31,164		
	zabeth Selby			No. 36,334		
Total Jan	· · · · · · · · · · · · · · · · · · ·		Anniviorgan Reg. N	0. 38,181		!
Send C	orrespondence to: David J. Levy, Pat	eart Councel			Direct Telephone Cal	Is to:
	Global Intellectual	l Property Department	22247	III I	Karen	I Drug
ħ.	Glaxo Wellcome In	nc.	23347		Karen L. Prus 919-483-2192	
isi	Five Moore Drive,		PATENT TRADEMARK OFFI	ICE		
- iy	Research Triangle	Park, NC 27709				
The state of the s	statements and t	that all statements made herein of melieved to be true; and further that the he like so made are punishable by fir may jeopardize the validity of the approximate the statement of the approximate the statement of the statement o	ese statements were m ne or imprisonment, o	nade with the or both, under	knowledge that will	Iful falca
	FULL NAME	FAMILY NAME	FIRST GIVEN NAME		SECOND GIVEN NAME/I	NITTIAY
2	OF INVENTOR	BROWN	Nathaniel		A.	HIIIAL,
£.#	INVENTOR'S					
0	SIGNATURE RESIDENCE &	CITY	dr. m. on the			
U	CITIZENSHIP	Cambridge	STATE OR FOREIGN CO	UNTRY	COUNTRY OF CITIZENS	HIP
	POST OFFICE	POST OFFICE ADDRESS	CITY		US STATE & ZIP CODE/COU	737TD3.1
1	ADDRESS	Glaxo Wellcome Inc.	Research Triang	de Park	NC 27709, US	INTRY
		Five Moore Drive, PO Box 13398	8	, ic I al K	110 27709, 03	
2	FULL NAME	FAMILY NAME	FIRST GIVEN NAME		SECOND GIVEN NAME/I	NITIAL
2	OF INVENTOR INVENTOR'S	CONDREAY	Lynn		D.	
	SIGNATURE					
0	RESIDENCE &	CITY	STATE OR FOREIGN CO	UNTRY	COUNTRY OF CITIZENS	HIP
	CITIZENSHIP	Raleigh	NC		US	
2	POST OFFICE ADDRESS	POST OFFICE ADDRESS Glaxo Wellcome Inc.	CITY	1. 7. 1	STATE & ZIP CODE/COU	NTRY
~	ADDICESS	Five Moore Drive, PO Box 13398	Research Triang	ge Park	NC 27709, US	
	FULL NAME	FAMILY NAME	FIRST GIVEN NAME		SECOND GIVEN NAME/II	NIVIVA V
2	OF INVENTOR	GRAY	Douglas		Fraser	MIIAL
Ge.	INVENTOR'S					
00	SIGNATURE	· funge	7		* 16 Marc	h 2001
0	RESIDENCE &	CITY Greenford	STATE OR FOREIGN COUNT	RY	COUNTRY OF CITIZENS	
	CITIZENSHIP POST OFFICE	POST OFFICE ADDRESS	$\frac{GB}{CITY}$	X	GB	
3	ADDRESS	Glaxo Wellcome plc	Greenford		STATE & ZIP CODE/COU Middlesex UB6 (
į		891-995, Greenford Road			THURSON ODO	ile, GD

Ü
Him
Ü
, Line
Sale.
rid E
-
-
-
the first of the second
C. H. C. S. C. C. S. H. C. S. C.
the first of the second

	ENT APPLI	CLARATION FOR UT	ED OF A TOTAL DATE	ATTORNEY'S DOCKET NUMBER PU3514USW
2	FULL NAME OF INVENTOR	RUBIN	FIRST GIVEN NAME Marc	SECOND GIVEN NAME/INITIAL
00	INVENTOR'S SIGNATURE	Mullo		3/13/01
0	RESIDENCE & CITIZENSHIP	Chapel Hill	NC COUNTRY	COUNTRY OF CITIZENSHIP US
4	POST OFFICE ADDRESS	POST OFFICE ADDRESS Glaxo Wellcome Inc.	Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709, US
		Five Moore Drive, PO Box 13398		